Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Editas Medicine (EDIT)

Editas Medicine (EDIT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 174,738
  • Shares Outstanding, K 97,619
  • Annual Sales, $ 32,310 K
  • Annual Income, $ -237,090 K
  • EBIT $ -187 M
  • EBITDA $ -187 M
  • 60-Month Beta 2.15
  • Price/Sales 3.28
  • Price/Cash Flow N/A
  • Price/Book 12.10

Options Overview Details

View History
  • Implied Volatility 151.65% (-113.19%)
  • Historical Volatility 85.67%
  • IV Percentile 89%
  • IV Rank 31.50%
  • IV High 326.62% on 02/05/26
  • IV Low 71.18% on 01/16/26
  • Expected Move (DTE 25) 0.3655 (19.34%)
  • Put/Call Vol Ratio 0.07
  • Today's Volume 2,419
  • Volume Avg (30-Day) 564
  • Put/Call OI Ratio 0.20
  • Today's Open Interest 12,090
  • Open Int (30-Day) 23,295
  • Expected Range 1.5245 to 2.2555

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.27
  • Number of Estimates 6
  • High Estimate -0.17
  • Low Estimate -0.34
  • Prior Year -0.55
  • Growth Rate Est. (year over year) +50.91%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.6600 +13.86%
on 02/05/26
2.1700 -12.90%
on 01/27/26
-0.2700 (-12.50%)
since 01/23/26
3-Month
1.6600 +13.86%
on 02/05/26
2.7000 -30.00%
on 12/11/25
-0.5300 (-21.90%)
since 11/21/25
52-Week
0.9100 +107.69%
on 04/07/25
4.5372 -58.34%
on 10/08/25
-0.0300 (-1.56%)
since 02/21/25

Most Recent Stories

More News
Editas Medicine to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today...

EDIT : 1.8900 (+5.59%)
Editas: Q3 Earnings Snapshot

Editas: Q3 Earnings Snapshot

EDIT : 1.8900 (+5.59%)
Editas Medicine Announces Third Quarter 2025 Results and Business Updates

In vivo  preclinical proof-of-concept data presented at AHA and ESGCT demonstrating >90% LDL-C reduction in non-human primates supports EDIT-401’s potential as a best-in-class, one-time therapy ...

EDIT : 1.8900 (+5.59%)
Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025

CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today...

EDIT : 1.8900 (+5.59%)
Longevity Biotech Surges as $72.6B Market Forecast Sparks Investment Rush

Issued on behalf of Avant Technologies Inc. VANCOUVER – Baystreet.ca News Commentary – The longevity and cell therapy sector has captured Wall Street's attention as market projections hit $72.6...

AUTL : 1.7300 (+3.59%)
AVAI : 0.3956 (-0.95%)
DNLI : 20.86 (+3.32%)
EDIT : 1.8900 (+5.59%)
XNCR : 11.57 (+1.40%)
Editas Medicine Unveils Promising Preclinical Data on EDIT-401

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Editas Medicine...

EDIT : 1.8900 (+5.59%)
Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress

CAMBRIDGE, Mass., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today reported  in vivo preclinical proof-of-concept data for EDIT-401,...

EDIT : 1.8900 (+5.59%)
Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences

CAMBRIDGE, Mass., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today...

EDIT : 1.8900 (+5.59%)
Healthcare Innovation Accelerates as Four Converging Forces Drive Early Intervention Focus

USA News Group News Commentary

VCYT : 35.75 (+0.34%)
QURE : 24.47 (+4.42%)
HUM : 181.16 (-4.57%)
AVAI : 0.3956 (-0.95%)
EDIT : 1.8900 (+5.59%)
Healthcare Innovation Accelerates as Four Converging Forces Drive Early Intervention Focus

/CNW/ -- America's aging demographics are creating unprecedented demand for precision healthcare solutions, with population projections showing nearly one in...

VCYT : 35.75 (+0.34%)
HUM : 181.16 (-4.57%)
QURE : 24.47 (+4.42%)
AVAI : 0.3956 (-0.95%)
EDIT : 1.8900 (+5.59%)

Business Summary

Editas Medicine is a development-stage genome editing biotech, which makes medicines to treat serious diseases using its proprietary genome editing platform based on the unique Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology. Though the company's discovery efforts target...

See More

Key Turning Points

3rd Resistance Point 2.0967
2nd Resistance Point 2.0033
1st Resistance Point 1.9467
Last Price 1.8900
1st Support Level 1.7967
2nd Support Level 1.7033
3rd Support Level 1.6467

See More

52-Week High 4.5372
Fibonacci 61.8% 3.1516
Fibonacci 50% 2.7236
Fibonacci 38.2% 2.2956
Last Price 1.8900
52-Week Low 0.9100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar